Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Shares Outstanding (Diluted Average): 2021-2023

Historic Shares Outstanding (Diluted Average) for Amylyx Pharmaceuticals (AMLX) over the last 3 years, with Dec 2023 value amounting to $70.0 million.

  • Amylyx Pharmaceuticals' Shares Outstanding (Diluted Average) rose 37.07% to $93.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.3 million, marking a year-over-year increase of 37.07%. This contributed to the annual value of $70.0 million for FY2023, which is 19.65% up from last year.
  • According to the latest figures from FY2023, Amylyx Pharmaceuticals' Shares Outstanding (Diluted Average) is $70.0 million, which was up 19.65% from $58.5 million recorded in FY2022.
  • Over the past 5 years, Amylyx Pharmaceuticals' Shares Outstanding (Diluted Average) peaked at $70.0 million during FY2023, and registered a low of $6.6 million during FY2021.
  • For the 3-year period, Amylyx Pharmaceuticals' Shares Outstanding (Diluted Average) averaged around $45.0 million, with its median value being $58.5 million (2022).
  • Data for Amylyx Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY spiked of 788.13% (in 2022) over the last 5 years.
  • Yearly analysis of 3 years shows Amylyx Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $6.6 million in 2021, then skyrocketed by 788.13% to $58.5 million in 2022, then grew by 19.65% to $70.0 million in 2023.